92:00

Miscellaneous
Therapeutic Agents

92:00

ALI	ENDF	RONA	ΥΤΕ	SOE	DIUM
-----	------	------	------------	-----	------

/ (95.0		
70 MG ORAL TAB	LET		
00002485184	AG-ALENDRONATE	AGP	\$ 1.7804
00002299712	ALENDRONATE	SIV	\$ 1.7804
00002352966	ALENDRONATE	SNS	\$ 1.7804
00002381494	ALENDRONATE SODIUM	AHI	\$ 1.7804
00002248730	APO-ALENDRONATE	APX	\$ 1.7804
00002388553	AURO-ALENDRONATE	AUR	\$ 1.7804
00002500175	JAMP ALENDRONATE SODIUM	JPC	\$ 1.7804
00002385031	JAMP-ALENDRONATE	JPC	\$ 1.7804
00002529394	M-ALENDRONATE	MTR	\$ 1.7804
00002394871	MINT-ALENDRONATE	MPI	\$ 1.7804
00002523116	NRA-ALENDRONATE	NRA	\$ 1.7804
00002284006	PMS-ALENDRONATE-FC	PMS	\$ 1.7804
00002270889	RIVA-ALENDRONATE	RIV	\$ 1.7804
00002288109	SANDOZ ALENDRONATE	SDZ	\$ 1.7804
00002261715	TEVA-ALENDRONATE	TEV	\$ 1.7804
00002245329	FOSAMAX	ORC	\$ 11.1325
ALENDRONATE S	ODIUM/ VITAMIN D3		
70 MG * 5,600 UNIT	ORAL TABLET		
00002454475	APO-ALENDRONATE/VITAMIN D3	APX	\$ 2.4348
00002519836	JAMP ALENDRONATE/ VITAMIN D3	JPC	\$ 2.4348
00002314940	FOSAVANCE	ORC	\$ 5.0920
ALLOPURINOL			
100 MG ORAL TA	BLET		
00000402818	APO-ALLOPURINOL	APX	\$ 0.0780
00002402769	APO-ALLOPURINOL	APX	\$ 0.0780
00002396327	MAR-ALLOPURINOL	MAR	\$ 0.0780
200 MG ORAL TA	BLET		
00000479799	APO-ALLOPURINOL	APX	\$ 0.1300
00002402777	APO-ALLOPURINOL	APX	\$ 0.1300
00002396335	MAR-ALLOPURINOL	MAR	\$ 0.1300
300 MG ORAL TA	BLET		
00000402796	APO-ALLOPURINOL	APX	\$ 0.2125
00002402785	APO-ALLOPURINOL	APX	\$ 0.2125
00002396343	MAR-ALLOPURINOL	MAR	\$ 0.2125
AZATHIOPRINE	-		
50 MG ORAL TAB	ILET		
00002242907	APO-AZATHIOPRINE	APX	\$ 0.5185
00002242307	TEVA-AZATHIOPRINE	TEV	\$ 0.5185
00002230819	IMURAN	APC	\$ 1.3820
		<i>,</i>	

92:00

BETAHISTINE DIHYDROCHLORIDE

8 MG ORAL TABL	ET		
00002449145	AURO-BETAHISTINE	AUR	\$ 0.0637
00002519682	M-BETAHISTINE	MTR	\$ 0.0637
00002538121	MINT-BETAHISTINE	MPI	\$ 0.0637
00002544911	NRA-BETAHISTINE	NRA	\$ 0.0637
00002280183	TEVA-BETAHISTINE	TEV	\$ 0.0637
16 MG ORAL TAB	LET		
00002449153	AURO-BETAHISTINE	AUR	\$ 0.1106
00002466449	BETAHISTINE	SNS	\$ 0.1106
00002519690	M-BETAHISTINE	MTR	\$ 0.1106
00002538148	MINT-BETAHISTINE	MPI	\$ 0.1106
00002544938	NRA-BETAHISTINE	NRA	\$ 0.1106
00002330210	PMS-BETAHISTINE	PMS	\$ 0.1106
00002280191	TEVA-BETAHISTINE	TEV	\$ 0.1106
00002243878	SERC	BGP	\$ 0.5681
CLODRONATE DIS	SODIUM		
400 MG ORAL CAI	PSULE		
00002245828	CLASTEON	SUN	\$ 1.2374
COLCHICINE			
0.6 MG ORAL TAB	BLET		
00000572349	COLCHICINE	ODN	\$ 0.2565
00002373823	JAMP-COLCHICINE	JPC	\$ 0.2565
00002402181	PMS-COLCHICINE	PMS	\$ 0.2565

92:00

COMPOUND PRESCRIPTION

INJECTION

00000999114 MISCELLANEOUS INJECTABLE COMPOUND XXX

0.0000

To determine eligibility of a compound, pharmacies can contact Alberta Blue Cross for verification.

In order for a compound to be eligible:

- the compounded prescription must contain in therapeutic dosage; one or more drug(s) identified as allowable Drug Benefits; or one or more chemical entities; and
- the compounded prescription must not duplicate a manufactured drug product, whether the drug product is or is not identified as an allowable Drug Benefit; and
- the compounded prescription must not include a chemical entitiy or drug product, with the exception of diluents or bases, specifically identified as not an allowable Drug Benefit.

To be used when the compound has been prepared and dispensed by a licensed community pharmacy.

INJECTION

00000999215 MISCELLANEOUS INJECTABLE COMPOUND XXX

0.0000

To determine eligibility of a compound, pharmacies can contact Alberta Blue Cross for verification.

In order for a compound to be eligible:

- the compounded prescription must contain in therapeutic dosage; one or more drug(s) identified as allowable Drug Benefits; or one or more chemical entities; and
- the compounded prescription must not duplicate a manufactured drug product, whether the drug product is or is not identified as an allowable Drug Benefit; and
- the compounded prescription must not include a chemical entitiy or drug product, with the exception of diluents or bases, specifically identified as not an allowable Drug Benefit.

To be used when the compound has been procured from a licensed compound and repackaging pharmacy and dispensed by a licensed community pharmacy.

92:00

COMPOUND PRESCRIPTION

00000999999 MISCELLANEOUS COMPOUND XXX \$ 0.0000

To determine eligibility of a compound, pharmacies can contact Alberta Blue Cross for verification.

In order for a compound to be eligible:

- the compounded prescription must contain in therapeutic dosage; one or more drug(s) identified as allowable Drug Benefits; or one or more chemical entities; and
- the compounded prescription must not duplicate a manufactured drug product, whether the drug product is or is not identified as an allowable Drug Benefit; and
- the compounded prescription must not include a chemical entitiy or drug product, with the exception of diluents or bases, specifically identified as not an allowable Drug Benefit.

To be used when the compound has been prepared and dispensed by a licensed community pharmacy.

00000999216 MISCELLANEOUS COMPOUND XXX \$

To determine eligibility of a compound, pharmacies can contact Alberta Blue Cross for verification.

In order for a compound to be eligible:

- the compounded prescription must contain in therapeutic dosage; one or more drug(s) identified as allowable Drug Benefits; or one or more chemical entities; and
- the compounded prescription must not duplicate a manufactured drug product, whether the drug product is or is not identified as an allowable Drug Benefit; and
- the compounded prescription must not include a chemical entitiy or drug product, with the exception of diluents or bases, specifically identified as not an allowable Drug Benefit.

To be used when the compound has been procured from a licensed compound and repackaging pharmacy and dispensed by a licensed community pharmacy.

0.0000

92:00

COMPOUND PRESCRIPTION

ORAL

00000999214 MISCELLANEOUS ORAL COMPOUND XXX \$ 0.0000

To determine eligibility of a compound, pharmacies can contact Alberta Blue Cross for verification.

In order for a compound to be eligible:

- the compounded prescription must contain in therapeutic dosage; one or more drug(s) identified as allowable Drug Benefits; or one or more chemical entities; and
- the compounded prescription must not duplicate a manufactured drug product, whether the drug product is or is not identified as an allowable Drug Benefit; and
- the compounded prescription must not include a chemical entitiy or drug product, with the exception of diluents or bases, specifically identified as not an allowable Drug Benefit.

To be used when the compound has been procured from a licensed compound and repackaging pharmacy and dispensed by a licensed community pharmacy.

ORAL

00000999113 MISCELLANEOUS ORAL COMPOUND XXX \$ 0.0000

To determine eligibility of a compound, pharmacies can contact Alberta Blue Cross for verification.

In order for a compound to be eligible:

- the compounded prescription must contain in therapeutic dosage; one or more drug(s) identified as allowable Drug Benefits; or one or more chemical entities; and
- the compounded prescription must not duplicate a manufactured drug product, whether the drug product is or is not identified as an allowable Drug Benefit; and
- the compounded prescription must not include a chemical entitiy or drug product, with the exception of diluents or bases, specifically identified as not an allowable Drug Benefit.

To be used when the compound has been prepared and dispensed by a licensed community pharmacy.

DIMETHYL SULFOXIDE					
50 % BLADDER IRRIGATION SOLUTION					
00000493392 RIMSO-50	MYP	\$	2.0102		
FLUNARIZINE HCL					
5 MG (BASE) ORAL CAPSULE					
00002246082 FLUNARIZINE	AAP	\$	0.9411		

92:00

LEUCOVORIN CAI				
• •	AL TABLET		ф	0.0770
00002496828	MINT-LEUCOVORIN	MPI	\$ \$	3.6776
00002493357 00002170493	RIVA LEUCOVORIN LEDERLE LEUCOVORIN CALCIUM	RIV PFI	э \$	3.6776 7.2466
10 MG / ML INJECT		PFI	Ф	7.2400
00002087316	LEUCOVORIN CALCIUM	TEV	\$	13.7886
NAFARELIN ACET	ATE			
2 MG / ML (BASE)	NASAL SOLUTION			
00002188783	SYNAREL	PFI	\$	55.7235
PAMIDRONATE D	ISODIUM			
For the products wit millilitre basis.	hin the following three groupings, pricir	ng has been establishe	ed on a	per
3 MG / ML INJECTI	ON			
00002244550	PAMIDRONATE DISODIUM	PFI	\$	3.0317
6 MG / ML INJECTI	ON			
00002244551	PAMIDRONATE DISODIUM	PFI	\$	9.0366
9 MG / ML INJECTI	ON			
00002244552	PAMIDRONATE DISODIUM	PFI	\$	9.0953
PENTOSAN POLY	SULFATE SODIUM			
100 MG ORAL CA	PSULE			
00002029448	ELMIRON	JAI	\$	2.8227
RISEDRONATE SO	DDIUM			
35 MG ORAL TAB	LET			
00002353687	APO-RISEDRONATE	APX	\$	1.6764
00002406306	AURO-RISEDRONATE	AUR	\$	1.6764
00002302209	PMS-RISEDRONATE	PMS	\$	1.6764
00002370255	RISEDRONATE	SNS	\$	1.6764
00002411407	RISEDRONATE-35	SIV	\$	1.6764
00002327295	SANDOZ RISEDRONATE	SDZ	\$	1.6764
00002298392	TEVA-RISEDRONATE	TEV	\$	1.6764
00002246896	ACTONEL	ABV	\$	11.6009
MISCELLANEOUS T	HERAPEUTIC AGENTS			
92:05 AL	LERGENIC EXTRACTS			

ALLERGY SERUM INJECTION

00000999981 ALLERGY SERUM

92:00

XXX

0.0000

92:08 5 ALFA REDUCTASE INHIBITORS

DUTASTERIDE			
0.5 MG ORAL CAP	SULE		
00002404206	APO-DUTASTERIDE	APX	\$ 0.2565
00002469308	AURO-DUTASTERIDE	AUR	\$ 0.2565
00002429012	DUTASTERIDE	SIV	\$ 0.2565
00002443058	DUTASTERIDE	SNS	\$ 0.2565
00002484870	JAMP DUTASTERIDE	JPC	\$ 0.2565
00002416298	MED-DUTASTERIDE	GMP	\$ 0.2565
00002428873	MINT-DUTASTERIDE	MPI	\$ 0.2565
00002490587	PRIVA-DUTASTERIDE	NRA	\$ 0.2565
00002424444	SANDOZ DUTASTERIDE	SDZ	\$ 0.2565
00002408287	TEVA-DUTASTERIDE	TEV	\$ 0.2565
00002247813	AVODART	GSK	\$ 1.9446
FINASTERIDE			
5 MG ORAL TABLE	ΕT		
00002365383	APO-FINASTERIDE	APX	\$ 0.3506
00002405814	AURO-FINASTERIDE	AUR	\$ 0.3506
00002355043	FINASTERIDE	AHI	\$ 0.3506
00002445077	FINASTERIDE	SNS	\$ 0.3506
00002447541	FINASTERIDE	SIV	\$ 0.3506
00002357224	JAMP-FINASTERIDE	JPC	\$ 0.3506
00002522489	M-FINASTERIDE	MTR	\$ 0.3506
00002389878	MINT-FINASTERIDE	MPI	\$ 0.3506
00002310112	PMS-FINASTERIDE	PMS	\$ 0.3506
00002455013	RIVA-FINASTERIDE	RIV	\$ 0.3506
00002348500	TEVA-FINASTERIDE	TEV	\$ 0.3506
00002010909	PROSCAR	ORC	\$ 2.1550

92:00 MISCELLANEOUS THERAPEUTIC AGENTS

92:36 DISEASE-MODIFYING ANTIRHEUMATIC AGENTS

LEFLUNOMIDE

RESTRICTED BENEFIT - This product is a benefit for the treatment of rheumatoid arthritis when the initial prescription is prescribed by a Specialist in Rheumatology or Internal Medicine.

10 MG ORAL TABLE	10	MG	ORAL	TABL	ET.
------------------	----	----	------	------	-----

00002478862	ACCEL-LEFLUNOMIDE	ACP	\$ 2.0000
00002256495	APO-LEFLUNOMIDE	APX	\$ 2.6433
00002351668	LEFLUNOMIDE	SNS	\$ 2.6433
00002543575	LEFLUNOMIDE	SIV	\$ 2.6433
00002551918	MAR-LEFLUNOMIDE	MAR	\$ 2.6433
00002283964	SANDOZ LEFLUNOMIDE	SDZ	\$ 2.6433
00002261251	TEVA-LEFLUNOMIDE	TEV	\$ 2.6433
00002241888	ARAVA	SAV	\$ 11.4440
20 MG ORAL TABL	_ET		
00002478870	ACCEL-LEFLUNOMIDE	ACP	\$ 2.0000
00002256509	APO-LEFLUNOMIDE	APX	\$ 2.6433
00002351676	LEFLUNOMIDE	SNS	\$ 2.6433
00002543583	LEFLUNOMIDE	SIV	\$ 2.6433
00002551926	MAR-LEFLUNOMIDE	MAR	\$ 2.6433
00002283972	SANDOZ LEFLUNOMIDE	SDZ	\$ 2.6433
00002261278	TEVA-LEFLUNOMIDE	TEV	\$ 2.6433
00002241889	ARAVA	SAV	\$ 11.4443

92:92 OTHER MISCELLANEOUS THERAPEUTIC AGENTS

ABOBOTULINUMT	OXINA		
300 IU / VIAL INJEC	TION		
00002460203	DYSPORT THERAPEUTIC	ISP	\$ 385.5600
500 IU / VIAL INJEC	TION		
00002456117	DYSPORT THERAPEUTIC	ISP	\$ 642.6000
BOTULINUMTOXIN PROTEIN	A(150KD), FREE FROM COMPLEXING		
50 UNIT / VIAL INJE	CTION		
00002371081	XEOMIN	MPC	\$ 168.9600
100 UNIT / VIAL INJI	ECTION		
00002324032	XEOMIN	MPC	\$ 337.9200
ONABOTULINUMT	OXINA		
50 UNIT INJECTION			
00002531577	BOTOX (50 UNIT/VIAL)	ABV	\$ 3.7485
100 UNIT INJECTION	N .		
00001981501	BOTOX (100 UNIT/VIAL)	ABV	\$ 3.7485
200 UNIT INJECTION	N		
00002531585	BOTOX (200 UNIT/VIAL)	ABV	\$ 3.7485